DOCSLIB.ORG

ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2018 (February 2018 Update)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2018 (February 2018 Update) ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2018 (February 2018 update) Afghanistan Dextropropoxyphene 200 000 Codeine 50 000 Difenoxin 1 Dextropropoxyphene 10 000 Dipipanone 1 Diphenoxylate 5 000 Ecgonine 2 Fentanyl 6 Etorphine 1 Methadone 20 000 Fentanyl 17 000 Morphine 8 000 Hydrocodone 10 000 Pethidine 90 000 Hydromorphone 4 000 Pholcodine 40 000 Ketobemidone 1 Albania Methadone 100 000 Cocaine 1 Morphine 1 550 000 Codeine 1 090 000 Nicomorphine 1 Fentanyl 280 Normethadone 1 Heroin 1 Opium 10 Methadone 7 000 Oxycodone 40 000 Morphine 7 500 Pethidine 50 000 Oxycodone 2 000 Phenoperidine 1 Pethidine 2 700 Pholcodine 1 Pholcodine 1 500 Piritramide 1 Remifentanil 9 Remifentanil 16 000 Sufentanil 2 Sufentanil 10 Algeria Thebaine 68 000 Alfentanil 350 Armenia Codeine 2 500 000 Codeine 3 000 Etorphine 1 Fentanyl 40 Fentanyl 500 Methadone 13 000 Methadone 4 000 Morphine 7 000 Morphine 9 000 Thebaine 15 Oxycodone 4 000 Trimeperidine 1 500 Pethidine 3 000 Aruba* Pholcodine 1 500 000 Alfentanil 3 Remifentanil 1 Bezitramide 1 Sufentanil 30 Cocaine 70 Andorra Codeine 85 Cannabis 2 000 Dextromoramide 1 Fentanyl 100 Dextropropoxyphene 85 Methadone 1 000 Fentanyl 200 Morphine 500 Hydrocodone 2 Oxycodone 2 000 Methadone 150 Pethidine 500 Morphine 540 Remifentanil 4 Opium 450 Angola Oxycodone 300 Alfentanil 7 Pethidine 404 Codeine 30 000 Piritramide 124 Dextromoramide 500 Remifentanil 19 Dihydrocodeine 500 Ascension Island* Diphenoxylate 500 Alfentanil 1 Fentanyl 8 Fentanyl 1 Methadone 2 000 Morphine 1 Morphine 6 000 Pethidine 1 Pethidine 6 000 Australia Sufentanil 5 3-Methylthiofentanyl 1 Anguilla Alfentanil 850 Codeine 500 Alpha-methylthiofentanyl 1 Fentanyl 1 Cannabis 2 500 000 Morphine 20 Cocaine 7 000 Pethidine 300 Codeine 5 100 000 Antigua and Barbuda* Conc. of poppy straw Cocaine 9 ACA 900 Codeine 169 AMA 1 700 Dihydrocodeine 15 AOA 5 550 Diphenoxylate 28 ATA 18 731 260 Fentanyl 1 Desomorphine 1 Morphine 6 Dextromoramide 5 Oxycodone 2 Dextropropoxyphene 150 000 Pethidine 338 Dihydrocodeine 130 000 Remifentanil 1 Diphenoxylate 45 000 Sufentanil 1 Dipipanone 1 Argentina Ecgonine 1 Alphaprodine 1 Etorphine 1 Bezitramide 1 Fentanyl 30 000 Cannabis 50 Hydrocodone 100 Cocaine 15 Hydromorphone 70 000 Codeine 650 000 Methadone 850 000 Dextromoramide 1 Morphine 850 000 1 ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2018 (February 2018 update) Oripavine 500 Morphine 400 000 Oxycodone 2 700 000 Oxycodone 10 000 Oxymorphone 1 000 Oxymorphone 300 000 Pethidine 35 000 Pethidine 790 000 Pethidine intermediate B 1 Barbados Pholcodine 900 000 Codeine 120 000 Remifentanil 800 Dihydrocodeine 900 Sufentanil 2 Fentanyl 24 Austria Heroin 1 Alfentanil 450 Hydromorphone 3 Cannabis 50 000 Methadone 137 Cocaine 2 500 Morphine 3 165 Codeine 500 000 Pethidine 6 094 Codeine-N-oxide 70 Remifentanil 125 Dextropropoxyphene 200 Sufentanil 1 Dihydrocodeine 650 000 Belarus Dihydromorphine 20 3-Methylfentanyl 1 Diphenoxylate 40 3-Methylthiofentanyl 1 Ecgonine 10 Acetyl-alpha-methylfentanyl 1 Ethylmorphine 20 Acetyldihydrocodeine 1 Etorphine 10 Alfentanil 1 Fentanyl 50 000 Alpha-methylfentanyl 1 Heroin 40 Alpha-methylthiofentanyl 1 Hydrocodone 20 Alphaprodine 1 Hydromorphone 180 000 Beta-hydroxy-3-methyl fentanyl 1 Methadone 130 000 Beta-Hydroxyfentanyl 1 Morphine 2 400 000 Cocaine 100 Morphine-N-oxide 30 Codeine 800 000 Nicomorphine 100 Dextromoramide 1 Opium 20 000 Dextropropoxyphene 1 000 Oripavine 100 Dihydrocodeine 1 Oxycodone 400 000 Dipipanone 1 Oxymorphone 500 Ecgonine 1 Pethidine 1 000 Ethylmorphine 50 Piritramide 24 000 Etorphine 1 Remifentanil 4 500 Fentanyl 1 200 Sufentanil 600 Heroin 1 Thebaine 110 Hydrocodone 1 Tilidine 100 Hydromorphone 3 000 Azerbaijan Levomoramide 1 Codeine 2 000 Methadone 30 000 Fentanyl 60 Morphine 10 000 Methadone 6 000 Morphine-N-oxide 1 Morphine 3 600 MPPP 1 Thebaine 30 Norcodeine 1 Trimeperidine 2 800 Normethadone 1 Bahamas* Normorphine 1 Alfentanil 1 Norpipanone 1 Cannabis 3 Oxycodone 1 Cocaine 3 Oxymorphone 1 Codeine 3 750 Para-fluorofentanyl 1 Dihydrocodeine 1 Pethidine 1 Fentanyl 23 Remifentanil 1 Heroin 1 Sufentanil 1 Hydrocodone 1 Thebaine 1 Hydromorphone 1 Thiofentanyl 1 Ketobemidone 1 Trimeperidine 30 000 Methadone 1 Belgium Morphine 750 Acetylfentanyl 1 Oxycodone 3 750 AH-7921 1 Oxymorphone 1 Alfentanil 350 Pethidine 6 000 Cannabis 60 000 Sufentanil 1 Cocaine 7 500 Bahrain Codeine 1 830 000 Codeine 15 913 Codeine-N-oxide 1 Etorphine 3 Dihydrocodeine 1 Fentanyl 50 Ecgonine 1 Methadone 132 Ethylmorphine 140 000 Morphine 7 000 Etorphine 2 Oxycodone 1 750 Fentanyl 35 000 Pethidine 10 675 Heroin 1 Remifentanil 110 Hydrocodone 200 Bangladesh Hydromorphone 12 000 Fentanyl 1 200 Methadone 285 000 Methadone 40 000 Morphine 140 000 2 ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2018 (February 2018 update) Morphine-N-oxide 1 Codeine 2 643 MT-45 1 Fentanyl 825 Nicomorphine 1 Heroin 2 Norcodeine 1 Methadone 1 235 Normorphine 1 Morphine 5 250 Opium 5 000 Oxycodone 4 Oripavine 1 Pethidine 412 Oxycodone 320 000 Pholcodine 15 750 Pethidine 40 000 Remifentanil 19 Pholcodine 22 000 Sufentanil 4 Piritramide 20 000 Thebaine 1 Remifentanil 900 Botswana Sufentanil 90 Alfentanil 9 Thebaine 1 Codeine 18 000 Tilidine 2 000 000 Dihydrocodeine 1 000 Belize Etorphine 20 Cocaine 100 Fentanyl 7 Codeine 10 000 Hydromorphone 1 000 Dextropropoxyphene 4 000 Morphine 10 000 Dihydrocodeine 50 Oxycodone 400 Diphenoxylate 50 Pethidine 40 000 Fentanyl 25 Remifentanil 1 Hydrocodone 100 Sufentanil 3 Hydromorphone 100 Tilidine 300 Methadone 1 000 Brazil Morphine 4 000 3-Methylfentanyl 10 Oxycodone 250 6-Monoacetylmorphine 10 Pethidine 4 200 Alfentanil 3 244 Benin Alphaprodine 10 Codeine 1 500 Anileridine 10 Fentanyl 500 Bezitramide 10 Morphine 2 200 Cannabis 90 120 Pethidine 3 500 Cannabis resin 10 Sufentanil 1 Coca leaf 10 Bermuda* Cocaine 100 Alfentanil 4 Codeine 4 939 358 Cannabis 1 Codeine-N-oxide 10 Cannabis resin 1 Dextromoramide 10 Cocaine 75 Dextropropoxyphene 10 Codeine 1 875 Difenoxin 10 Dextromoramide 6 Dihydrocodeine 10 Dextropropoxyphene 1 Diphenoxylate 10 Dihydrocodeine 750 Dipipanone 10 Diphenoxylate 55 Ethylmorphine 10 Dipipanone 1 Etorphine 1 Etorphine 2 Fentanyl 5 887 Fentanyl 23 Heroin 10 Heroin 1 Hydrocodone 10 Hydrocodone 6 Hydromorphone 4 746 Hydromorphone 57 Ketobemidone 10 Methadone 1 500 Levorphanol 10 Morphine 563 Methadone 95 027 Oxycodone 320 Morphine 2 056 081 Oxymorphone 1 Morphine-N-oxide 10 Pethidine 1 125 Nicomorphine 10 Pholcodine 38 Norcodeine 10 Remifentanil 8 Normethadone 10 Bhutan Opium 165 740 Codeine 500 Oripavine 10 Etorphine 1 Oxycodone 174 614 Fentanyl 2 Oxymorphone 10 Morphine 570 Pethidine 682 250 Pethidine 700 Pethidine intermediate B 10 Bolivia (Plurinational State of) Phenoperidine 10 Codeine 323 140 Pholcodine 10 Fentanyl 60 Piritramide 1 Morphine 79 390 Racemoramide 10 Oxycodone 27 062 Remifentanil 5 533 Pethidine 17 400 Thebacon 10 Remifentanil 150 Thebaine 10 Bosnia and Herzegovina* Tilidine 10 Alfentanil 19 British Virgin Islands Cannabis 2 Codeine 200 Cannabis resin 2 Dihydrocodeine 30 Cocaine 2 Diphenoxylate 10 3 ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2018 (February 2018 update) Fentanyl 20 Morphine 8 000 Hydromorphone 2 Pethidine 8 000 Morphine 200 Pholcodine 1 500 Oxycodone 100 Canada Pethidine 650 3-Methylfentanyl 10 Remifentanil 1 3-Methylthiofentanyl 1 Brunei Darussalam Acetyl-alpha-methylfentanyl 5 Alfentanil 2 Acetyldihydrocodeine 1 Codeine 5 000 Acetylmethadol 5 Dihydrocodeine 1 000 Alfentanil 150 Fentanyl 55 Allylprodine 5 Morphine 1 200 Alphacetylmethadol 3 Oxycodone 250 Alphameprodine 5 Pethidine 1 200 Alphamethadol 5 Pholcodine 1 000 Alpha-methylfentanyl 1 Remifentanil 3 Alpha-methylthiofentanyl 1 Bulgaria Alphaprodine 5 Alfentanil 10 Anileridine 1 Cocaine 1 Benzethidine 1 Codeine 4 000 000 Beta-Hydroxyfentanyl 1 Codeine-N-oxide 5 Betameprodine 1 Dextropropoxyphene 500 Cannabis resin 481 500 Diampromide 1 Cocaine 20 000 Dihydrocodeine 15 000 Codeine 17 500 000 Ecgonine 2 Desomorphine 1 Ethylmorphine 10 000 Dextromoramide 1 Fentanyl 600 Dextropropoxyphene 100 Heroin 1 Diethylthiambutene 5 Hydrocodone 1 Difenoxin 5 Hydromorphone 1 Dihydrocodeine 2 Isomethadone 5 Dihydromorphine 3 100 Methadone 150 000 Dimethylthiambutene 5 Morphine 50 000 Dioxaphetyl butyrate 5 Morphine-N-oxide 2 Diphenoxylate 5 000 Normorphine 1 Dipipanone 5 Opium 10 Drotebanol 5 Oxycodone 35 000 Ecgonine 1 Oxymorphone 1 Ethylmorphine 3 Pethidine 20 000 Etonitazene 5 Piritramide 1 000 Etorphine 5 Remifentanil 35 Etoxeridine 5 Sufentanil 10 Fentanyl 100 000 Tilidine 10 000 Furethidine 5 Burkina Faso Heroin 60 000 Dextromoramide 1 Hydrocodone 85 000 Fentanyl 7 Hydromorphinol 1 Morphine 2 752 Hydromorphone 2 100 000 Pethidine 35 Isomethadone 5 Sufentanil 1 Ketobemidone 2 Burundi Levomethorphan 5 Codeine 1 000 Levophenacylmorphan 5 Fentanyl 2 Levorphanol 25 Morphine 3 000 Methadone 2 500 000 Pethidine 1 000 Morpheridine 25 Cabo Verde Morphine 4 000 000 Alfentanil 1 Morphine-N-oxide 5 Cannabis 1 MPPP 25 Cannabis resin 1 Norcodeine 1 Cocaine 1 Normethadone 10 000 Codeine 40 Normorphine 1 Fentanyl 4 Norpipanone 25 Heroin 1 Opium 7 000 Methadone 8 Oripavine 15 000 Morphine 220 Oxycodone 9 000 000 Pethidine 200 Oxymorphone 20 000 Cambodia* Para-fluorofentanyl 1 Codeine 116 500 Pethidine 400 000 Fentanyl 19 Phenadoxone 25 Methadone 5 625 Phenampromide 5 Morphine 10 000 Phenazocine 10 Oxycodone 2 000 Phenomorphan 1 Pethidine 500 Phenoperidine 25 Cameroon* Pholcodine 20 Codeine 40 000 Piminodine 25 Fentanyl 5 Piritramide 5 4 ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS
Load more

Recommended publications
  • Minnesota Statutes 1979 Supplement
    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
    [Show full text]
  • The Use of Nitrous Oxide Gas for Lower Gastrointestinal Endoscopy Sophie Welchman, Sean Cochrane, Gary Minto, Stephen Lewis
    Systematic review: The use of nitrous oxide gas for lower gastrointestinal endoscopy Sophie Welchman, Sean Cochrane, Gary Minto, Stephen Lewis To cite this version: Sophie Welchman, Sean Cochrane, Gary Minto, Stephen Lewis. Systematic review: The use of nitrous oxide gas for lower gastrointestinal endoscopy. Alimentary Pharmacology and Therapeutics, Wiley, 2010, 32 (3), pp.324. 10.1111/j.1365-2036.2010.04359.x. hal-00552574 HAL Id: hal-00552574 https://hal.archives-ouvertes.fr/hal-00552574 Submitted on 6 Jan 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Alimentary Pharmacology & Therapeutic Systematic review: The use of nitrous oxide gas for lower gastrointestinal endoscopy ForJournal: Alimentary Peer Pharmacology Review & Therapeutics Manuscript ID: APT-0287-2010.R1 Manuscript Type: Systematic Review Date Submitted by the 13-May-2010 Author: Complete List of Authors: Welchman, Sophie; Derriford Hospital, Surgery Cochrane, Sean; Derriford Hospital, Gastroenterology Minto, Gary; Derriford Hospital, Anaesthesia Lewis, stephen; Derriford Hospital,
    [Show full text]
  • Screening/Spot Test of Narcotics
    Indian Journal of Forensic and Community Medicine 2020;7(4):160–165 Content available at: https://www.ipinnovative.com/open-access-journals Indian Journal of Forensic and Community Medicine Journal homepage: https://www.ipinnovative.com/journals/IJFCM Review Article Screening/spot test of narcotics A K Jaiswal1,*, Kamna Sharma2, Rohit Kanojia3, Sally Lukose4 1Dept. of Forensic Medicine & Toxicology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India 2Galgotias University, Greater Noida, Uttar Pradesh, India 3Dept. of Chemistry, University of Delhi, New Delhi, India 4CTM-IRTE, Faridabad, Haryana, India ARTICLEINFO ABSTRACT Article history: Narcotics are the substances used to treat moderate to severe pain. They could be natural like opiates such Received 25-11-2020 as morphine, codeine etc., synthetic like fentanyl, methadone etc., and semi-synthetic like oxycodone, Accepted 02-12-2020 hydrocodone etc. These drugs act as pain relievers, induces the state of stupor or sleep, and increase Available online 08-01-2021 the physical dependence on them. In forensic autopsy case, the forensic pathologist may require a complete toxicological investigation for different poisons including stimulants. In India, Forensic Science Laboratories run by Government under the Home ministry usually carry out this. The samples must be Keywords: analysed by the forensic toxicologist/chemists/scientist. This article deals with the screening/spot test for Narcotics narcotics. It attempts to simplify the standard procedures in a step-wise manner, which can be of handy Screening reference for the forensic toxicologist. Spot test Drugs © This is an open access article distributed under the terms of the Creative Commons Attribution Opioids etc License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
    [Show full text]
  • 2020 Kansas Statutes
    2020 Kansas Statutes 65-4105. Substances included in schedule I. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide) 9821 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide) 9815 (3) Acetylmethadol 9601 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551 (6) Allylprodine 9602 (7) Alphacetylmethadol 9603(except levo-alphacetylmethadol also known as levo- alpha-acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine 9604 (9) Alphamethadol 9605 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) 9814 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide) 9832 (12) Benzethidine 9606 (13) Betacetylmethadol 9607 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide) 9830 (15) Beta-hydroxy-3-methylfentanyl (other
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • Ketamine for Chronic Non- Cancer Pain: a Review of Clinical Effectiveness, Cost- Effectiveness, And
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Ketamine for Chronic Non- Cancer Pain: A Review of Clinical Effectiveness, Cost- Effectiveness, and Guidelines Service Line: Rapid Response Service Version: 1.0 Publication Date: May 28, 2020 Report Length: 28 Pages Authors: Khai Tran, Suzanne McCormack Cite As: Ketamine for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa: CADTH; 2020 May. (CADTH rapid response report: summary with critical appraisal) ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
    [Show full text]
  • Best Bets from the Manchester Royal Infirmary Edited by K Mackway-Jones
    247 BEST EVIDENCE TOPIC REPORTS Emerg Med J: first published as 10.1136/emj.19.3.248 on 1 May 2002. Downloaded from Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary Edited by K Mackway-Jones Clinical scenario Best evidence topic reports (BETs) summarise the evidence A 23 year old woman attends an emergency department hav- pertaining to particular clinical questions. They are not ing taken sixty 500 mg paracetamol tablets. Her four hour systematic reviews, but rather contain the best (highest paracetamol levels are above the treatment line. She does not level) evidence that can be practically obtained by busy want to be treated with intravenous therapy. You wonder practising clinicians. The search strategies used to find the whether oral antidote is as effective. best evidence are reported in detail in order to allow clinicians to update searches whenever necessary. The BETs published below were first reported at the Critical Three part question Appraisal Journal Club at the Manchester Royal Infirmary.1 In [patients who need an antidote for paracetamol overdose] Each BET has been constructed in the four stages that have is [intravenous therapy better than oral therapy] at [prevent- been described elsewhere.2 The BETs shown here together ing liver damage and death]? with those published previously and those currently under construction can be seen at http://www.bestbets.org.3 Six Search strategy BETs are included in this issue of the journal. Medline 1966 to 12/01 using the OVID interface. [exp acetyl-
    [Show full text]
  • High Rates of Tramadol Use Among Treatment-Seeking Adolescents in Malmö, Sweden: a Study of Hair Analysis of Nonmedical Prescription Opioid Use
    Hindawi Journal of Addiction Volume 2017, Article ID 6716929, 9 pages https://doi.org/10.1155/2017/6716929 Research Article High Rates of Tramadol Use among Treatment-Seeking Adolescents in Malmö, Sweden: A Study of Hair Analysis of Nonmedical Prescription Opioid Use Martin O. Olsson,1 Agneta Öjehagen,1 Louise Brådvik,1 Robert Kronstrand,2,3 and Anders Håkansson1 1 Psychiatry, Department of Clinical Sciences, Lund, Faculty of Medicine, Lund University, 221 00 Lund, Sweden 2Department of Forensic Genetics and Forensic Toxicology, Swedish National Board of Forensic Medicine, Linkoping,¨ Sweden 3Division of Drug Research, Linkoping¨ University, 581 85 Linkoping,¨ Sweden Correspondence should be addressed to Martin O. Olsson; martin [email protected] Received 21 September 2017; Accepted 6 December 2017; Published 24 December 2017 Academic Editor: Leandro F. Vendruscolo Copyright © 2017 Martin O. Olsson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Nonmedical prescription opioid use (NMPOU) is a growing problem and tramadol has been suggested as an emerging problem in young treatment-seeking individuals. The aim of the present study was to investigate, through hair analysis, NMPOU in this group and, specifically, tramadol use. Methods. In a study including 73 treatment-seeking adolescents and young adults at an outpatient facility for young substance users, hair specimens could be obtained from 59 subjects. Data were extracted on sociodemographic background variables and psychiatric diagnoses through MINI interviews. Results. In hair analysis, tramadol was by far the most prevalent opioid detected.
    [Show full text]
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun
    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
    [Show full text]
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence
    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub
    US 2004.0024006A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub. Date: Feb. 5, 2004 (54) OPIOID PHARMACEUTICAL May 30, 1997, now abandoned, and which is a COMPOSITIONS continuation-in-part of application No. 08/643,775, filed on May 6, 1996, now abandoned. (76) Inventor: David Lew Simon, Mansfield Center, CT (US) Publication Classification Correspondence Address: (51) Int. Cl. ................................................ A61K 31/485 David L. Simon (52) U.S. Cl. .............................................................. 514/282 P.O. Box 618 100 Cemetery Road (57) ABSTRACT Mansfield Center, CT 06250 (US) The invention is directed in part to dosage forms comprising a combination of an analgesically effective amount of an (21) Appl. No.: 10/628,089 opioid agonist analgesic and a neutral receptor binding agent or a partial mu-opioid agonist, the neutral receptor binding (22) Filed: Jul. 25, 2003 agent or partial mu-opioid agonist being included in a ratio Related U.S. Application Data to the opioid agonist analgesic to provide a combination product which is analgesically effective when the combina (63) Continuation-in-part of application No. 10/306,657, tion is administered as prescribed, but which is leSS analge filed on Nov. 27, 2002, which is a continuation-in-part Sically effective or less rewarding when administered in of application No. 09/922,873, filed on Aug. 6, 2001, excess of prescription. Preferably, the combination product now Pat. No. 6,569,866, which is a continuation-in affects an opioid dependent individual differently from an part of application No. 09/152,834, filed on Sep.
    [Show full text]